

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/666,144	09/20/2000	Vaijayanti A. Kumar	273944	5793
26694 7	590 01/27/2006		EXAMINER	
VENABLE LLP			ANGELL, JON E	
P.O. BOX 343	85 N, DC 20045-9998		ART UNIT	PAPER NUMBER
WASHINGTO	N, DC 20043-3336		1635	

DATE MAILED: 01/27/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Summan	09/666,144	KUMAR				
Office Action Summary	Examiner	Art Unit				
	Jon Eric Angell	1635				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with	the correspondence address -				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICA 16(a). In no event, however, may a reply fill apply and will expire SIX (6) MONTHS cause the application to become ABANI	TION. be timely filed from the mailing date of this communical DONED (35 U.S.C. § 133).	•			
Status						
1) Responsive to communication(s) filed on 29 Se	entember 2005 and 31 Octob	ner 2005				
	action is non-final.					
3) Since this application is in condition for allowan		prosecution as to the merits	ie			
closed in accordance with the practice under E	·	·				
Disposition of Claims		., 100 0.0.210.				
4) Claim(s) <u>14-20 and 22-26</u> is/are pending in the						
4a) Of the above claim(s) is/are withdraw	n from consideration.	•				
5) Claim(s) <u>14-20 and 24-26</u> is/are allowed.						
6) Claim(s) 23 and 24 is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	election requirement.					
Application Papers						
9) The specification is objected to by the Examiner	9) The specification is objected to by the Examiner.					
)⊠ The drawing(s) filed on <u>20 September 2000</u> is/are: a)□ accepted or b)⊠ objected to by the Examiner.					
Applicant may not request that any objection to the d						
Replacement drawing sheet(s) including the correction			(d)			
11) The oath or declaration is objected to by the Exa						
Priority under 35 U.S.C. § 119						
<u> </u>	oriority under 25 H C C C 44	0(a) (d) a (5)				
12) Acknowledgment is made of a claim for foreign pa) All b) Some * c) None of:	priority under 35 U.S.C. § 11	9(a)-(d) or (f).				
<u> </u>	have been seed					
2. Certified copies of the priority documents						
3. Copies of the certified copies of the priori		eived in this National Stage				
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of	of the certified copies not rec	eived.	•			
Attachment(s)			•			
Notice of References Cited (PTO-892)	4) X Interview Sumi	mary (PTO-413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/M	ail Date. <u>attached</u> .				
B) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	5)	nal Patent Application (PTO-152)				
· akar malakman anna,	о, 🗀 ошет					

Application/Control Number: 09/666,144

Art Unit: 1635

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 9/29/2005 has been entered.

The amendment filed 9/29/2005 is acknowledged. The amendment filed 9/29/2005 has been entered. Claims 14-20, 22-26 are currently pending in the application and are addressed herein.

Applicant's arguments are addressed on a per section basis. The text of those sections of Title 35, U.S. Code not included in this Action can be found in a prior Office Action. Any rejections not reiterated in this action have been withdrawn as being obviated by the amendment of the claims and/or applicant's arguments.

Drawings

The drawings are objected to as failing to comply with 37 CFR 1.84(p)(5) because they include the following reference character(s) not mentioned in the description: Figure 9A, Figure 9B, Figure 10A and Figure 10B. Furthermore, it appears that there is one Figure 9, two Figures 9A and one Figure 9B, however the specification only describes the drawing of Figure 9. It also appears that there are two Figure 10As and two Figure 10Bs (and no Figure 10 without the designation A or B), however the specification only describes the drawing of "Figure 10".

Art Unit: 1635

Corrected drawing sheets in compliance with 37 CFR 1.121(d), or amendment to the specification to add the reference character(s) in the description in compliance with 37 CFR 1.121(b) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either "Replacement Sheet" or "New Sheet" pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.

Claim Rejections - 35 USC § 112, 2nd paragraph/35 USC §101

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 22 and 23 provides for the use of the compounds 4a and 6a, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced.

Claims 22 and 23 are also rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example *Ex parte Dunki*, 153 USPQ 678 (Bd.App. 1967) and *Clinical Products*, *Ltd.* v. *Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

It is noted that amending the claims to include language which sets for the method step(s) which are performed in order to "use" the compounds of formulae 4a and 6a for sequence specific recognition of the compounds of claims 14 and 15 would obviate the instant rejection(s).

Additionally, claims 22 and 23 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 22 recites the limitation "a single of double stranded polynucleotide DNA or RNA compound according to claim 14". There is insufficient antecedent basis for this limitation in the claim because claim 14 does not recite any single of double stranded polynucleotide DNA or RNA compound.

Claim 23 recites the limitation "a single of double stranded polynucleotide DNA or RNA compound according to claim 15". There is insufficient antecedent basis for this limitation in the claim because claim 15 does not recite any single of double stranded polynucleotide DNA or RNA compound.

Application/Control Number: 09/666,144

Art Unit: 1635

It is noted that amending claims 22 and 23 to remove the phrase "a single of double

stranded polynucleotide DNA or RNA" would obviate this rejection.

Allowable Subject Matter

Claims 14-20, 24-26 are allowed.

Conclusion

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Jon Eric Angell whose telephone number is 571-272-0756. The

examiner can normally be reached on Mon-Fri, with every other Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Andrew Wang can be reached on 571-272-0811. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

J.E. Angell, Ph.D.

Patent Examiner

AU 1635

Page 5